These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731 [TBL] [Abstract][Full Text] [Related]
24. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics. Weiss E; Kemmler G; Fleischhacker WW Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210 [No Abstract] [Full Text] [Related]
25. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
26. New drugs for the treatment of schizophrenic patients. Fleischhacker WW Acta Psychiatr Scand Suppl; 1995; 388():24-30. PubMed ID: 7604735 [TBL] [Abstract][Full Text] [Related]
27. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123 [TBL] [Abstract][Full Text] [Related]
28. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. Han M; Zhang XY; Chen DC; Tan YL; Song CS; Yu YH; Huang XF Int Clin Psychopharmacol; 2015 Mar; 30(2):89-95. PubMed ID: 25568968 [TBL] [Abstract][Full Text] [Related]
29. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Harvey PD; Sacchetti E; Galluzzo A; Romeo F; Gorini B; Bilder RM; Loebel AD Schizophr Res; 2008 Oct; 105(1-3):138-43. PubMed ID: 18077136 [TBL] [Abstract][Full Text] [Related]
30. Cognitive function in schizophrenia--do neuroleptics make a difference? Mortimer AM Pharmacol Biochem Behav; 1997 Apr; 56(4):789-95. PubMed ID: 9130306 [TBL] [Abstract][Full Text] [Related]
31. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Heinrichs RW Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745 [No Abstract] [Full Text] [Related]
32. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I; J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069 [TBL] [Abstract][Full Text] [Related]
34. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications. Savina I; Beninger RJ Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766 [TBL] [Abstract][Full Text] [Related]
35. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239 [TBL] [Abstract][Full Text] [Related]
36. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911 [TBL] [Abstract][Full Text] [Related]
37. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M; Keefe RS Schizophr Res; 1995 Sep; 17(1):123-9. PubMed ID: 8541245 [No Abstract] [Full Text] [Related]
38. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Keefe RS; Silva SG; Perkins DO; Lieberman JA Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727 [TBL] [Abstract][Full Text] [Related]
39. On the trail of a cognitive enhancer for the treatment of schizophrenia. Stip E; Chouinard S; Boulay LJ Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228 [TBL] [Abstract][Full Text] [Related]
40. Olanzapine: an updated review of its use in the management of schizophrenia. Bhana N; Foster RH; Olney R; Plosker GL Drugs; 2001; 61(1):111-61. PubMed ID: 11217867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]